Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis

Margarita Kunin, Vered Carmon, Michael Arad, Nomy Levin-Iaina, Dov Freimark, Eli J. Holtzman, Dganit Dinour

Research output: Contribution to journalArticlepeer-review

Abstract

Proinflammatory cytokines play a pathogenic role in congestive heart failure. In this study, the effect of peritoneal dialysis treatment on inflammatory cytokines levels in refractory congestive heart failure patients was investigated. During the treatment, the patients reached a well-tolerated edema-free state and demonstrated significant improvement in NYHA functional class. Brain natriuretic peptide decreased significantly after 3 months of treatment and remained stable at 6 months. C-reactive protein, a plasma marker of inflammation, decreased significantly following the treatment. Circulating inflammatory cytokines TNF-α and IL-6 decreased significantly after 3 months of peritoneal dialysis treatment and remained low at 6 months. The reduction in circulating inflammatory cytokines levels may be partly responsible for the efficacy of peritoneal dialysis for refractory congestive heart failure.

Original languageEnglish
Article number590851
JournalBioMed Research International
Volume2015
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis'. Together they form a unique fingerprint.

Cite this